Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials
Executive Summary
GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.
You may also be interested in...
Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.
Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.
Lamictal IR Experience Impresses Advisory Committee, Not XR Trial Design
Committee members recommend Lamictal XR as a monotherapy for partial seizures, relying on the knowledge that the immediate-release version of the drug works for the indication.